Nuvalent reports $17.3M Q4 loss; IND cleared for ALK inhibitor NVL-655

Nuvalent, Inc.

Q4 2021 net loss $17.3M; full-year net loss $46.3M, vs $14.6M in 2020.
Cash, equivalents, marketable securities $288.1M as of Dec 31, 2021; runway into 2024.
FDA cleared IND for NVL-655 (ALK-selective); ALKOVE-1 Phase 1/2 to start Q2 2022.
ARROS-1 trial of NVL-520 (ROS1) actively enrolling Phase 1 patients.
Discovery pipeline targeting ALK resistance and HER2 exon 20; 2 candidate nominations expected in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.